FDA Approves Retrophin’s New Formula for Cystine Kidney Stones

Retrophin, based in San Diego, announced that the U.S. Food and Drug Administration (FDA) had given its 100 mg and 300 mg tablets of Thiola EC (tiopronin) the thumbs-up to treat cystinuria. Cystinuria is a rare inherited disease that results in a buildup of cystine levels in the urine, causing the development of recurring cystine kidney stones.